ERBB2 and breast cancer: Because neoadjuvant chemotherapy is increasingly used in breast cancer patients to facilitate BCT and because response to neoadjuvant chemotherapy has been shown to provide prognostic information, we undertook the current study to determine if categorizing patients into subgroups using ER, PR and HER2 status could predict response to neoadjuvant chemotherapy and identify patients at high risk for local-regional recurrence (LRR) following neoadjuvant chemotherapy and BCT.